Skip to main content
. Author manuscript; available in PMC: 2016 Feb 20.
Published in final edited form as: Int J Pharm. 2014 Dec 24;479(2):329–337. doi: 10.1016/j.ijpharm.2014.12.052

Table 2.

Summary of ReleaseStudy Data

Sample Amaxa (%, mean ± SD) Tmaxb (minutes) Cmaxc (ng/mL, mean ± SD) C6d (ng/mL, mean ± SD)
A1 33.5 ± 6.6 15 198.7 ± 29.1 68.1 ± 7.6
B1 42.4 ± 2.8 15 249.2 ± 35.5 65.6 ± 17.3
C1 9.2 ± 3.6 30 52.9 ± 19.7 2.4 ± 3.4
A2 41.3 ± 2.0 15 137.5 ± 2.0 BDL
B2 32.7 ± 11.8 15 112.4 ± 41.5 18.2 ± 25.8
C2 16.1 ± 1.7 30 67.2 ± 7.3 10.6 ± 14.9
a

maximum amount (μg) measured in solution as a percentage of the initial amount of drug (μg)

b

time period at which maximum amount measured

c

maximum concentration (ng/mL) measured in solution

d

concentration (ng/mL) measured at the 6 hour time period

BDL = below detectable limit